In vivo chemical exchange saturation transfer imaging allows early detection of a therapeutic response in glioblastoma
Open Access
- 10 March 2014
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 111 (12), 4542-4547
- https://doi.org/10.1073/pnas.1323855111
Abstract
Glioblastoma multiforme (GBM), which account for more than 50% of all gliomas, is among the deadliest of all human cancers. Given the dismal prognosis of GBM, it would be advantageous to identify early biomarkers of a response to therapy to avoid continuing ineffective treatments and to initiate other therapeutic strategies. The present in vivo longitudinal study in an orthotopic mouse model demonstrates quantitative assessment of early treatment response during short-term chemotherapy with temozolomide (TMZ) by amide proton transfer (APT) imaging. In a GBM line, only one course of TMZ (3 d exposure and 4 d rest) at a dose of 80 mg/kg resulted in substantial reduction in APT signal compared with untreated control animals, in which the APT signal continued to increase. Although there were no detectable differences in tumor volume, cell density, or apoptosis rate between groups, levels of Ki67 (index of cell proliferation) were substantially reduced in treated tumors. In another TMZ-resistant GBM line, the APT signal and levels of Ki67 increased despite the same course of TMZ treatment. As metabolite changes are known to occur early in the time course of chemotherapy and precede morphologic changes, these results suggest that the APT signal in glioma may be a useful functional biomarker of treatment response or degree of tumor progression. Thus, APT imaging may serve as a sensitive biomarker of early treatment response and could potentially replace invasive biopsies to provide a definitive diagnosis. This would have a major impact on the clinical management of patients with glioma.Keywords
This publication has 46 references indexed in Scilit:
- Advances in the management of glioblastoma: the role of temozolomide and MGMT testingClinical Pharmacology: Advances and Applications, 2012
- Molecular mechanisms of temozolomide resistance in glioblastoma multiformeExpert Review of Anticancer Therapy, 2012
- Pseudoprogression: Relevance With Respect to Treatment of High-Grade GliomasCurrent Treatment Options in Oncology, 2011
- Pseudoprogression and Pseudoresponse: Imaging Challenges in the Assessment of Posttreatment GliomaAmerican Journal Of Neuroradiology, 2011
- Regulation of cancer cell metabolismNature Reviews Cancer, 2011
- MR imaging of high-grade brain tumors using endogenous protein and peptide-based contrastNeuroImage, 2010
- The Telomerase Antagonist, Imetelstat, Efficiently Targets Glioblastoma Tumor-Initiating Cells Leading to Decreased Proliferation and Tumor GrowthClinical Cancer Research, 2010
- Amide proton transfer imaging of human brain tumors at 3TMagnetic Resonance in Medicine, 2006
- Protein degradation and the generation of MHC class I-presented peptidesAdvances in Immunology, 2002
- Morphological effects of chemotherapy on ovarian carcinomaJournal of Clinical Pathology, 2002